Literature DB >> 27141285

Effect of Thymoquinone on P53 Gene Expression and Consequence Apoptosis in Breast Cancer Cell Line.

Mehdi Nikbakht Dastjerdi1, Ebrahim Momeni Mehdiabady1, Farhad Golshan Iranpour1, Hamid Bahramian1.   

Abstract

BACKGROUND: Nigella sativa has been a nutritional flavoring factor and natural treatment for many ailments for so many years in medical science. Earlier studies have been reported that thymoquinone (TQ), an active compound of its seed, contains anticancer properties. Previous studies have shown that TQ induces apoptosis in breast cancer cells but it is unclear the role of P53 in the apoptotic pathway. Hereby, this study reports the potency of TQ on expression of tumor suppressor gene P53 and apoptosis induction in breast cancer cell line Michigan Cancer Foundation-7 (MCF-7).
METHODS: MCF-7 cell line was cultured and treated with TQ, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was carried out for evaluating the half-maximal inhibitory concentration (IC50) values after 24 h of treatment. The percentage of apoptotic cells was measured by flow cytometry. Real-time polymerase chain reaction (PCR) was performed to estimate the messenger RNA expression of P53 in MCF-7 cell line at different times.
RESULTS: The IC50 value for the TQ in MCF-7 cells was 25 μM that determined using MTT assay. The flow cytometry and real-time PCR results showed that TQ could induce apoptosis in MCF-7 cells, and the P53 gene expression was dramatically up-regulated by ascending time, respectively. Hence, there was significant difference in 48 and 72 h.
CONCLUSIONS: Our results demonstrated that TQ could induce apoptosis in MCF-7 cells through up-regulation of P53 expression in breast cancer cell line (MCF-7) by time-dependent manner.

Entities:  

Keywords:  Apoptosis; Michigan C]ancer Foundation-7 cells; genes P53; thymoquinone

Year:  2016        PMID: 27141285      PMCID: PMC4837800          DOI: 10.4103/2008-7802.180412

Source DB:  PubMed          Journal:  Int J Prev Med        ISSN: 2008-7802


INTRODUCTION

Breast cancer is the most common cancer among women worldwide and it has been reported that each year about 502,000 die from the disease.[12] Breast cancer originates in the breast but metastasizes to other distant organs such as bone, lungs, and brain.[3] Global statistics showed that by the year 2020, there will be twenty million new cancer patients every year.[4] Herbal medications are the source of many chemotherapeutic agents and it has also been demonstrated to have anti-neoplastic potential (Nigella sativa, paclitaxel, vincristine, etc.).[5] Thymoquinone (TQ) is as a potential chemo preventive and chemotherapeutic compound of oil of the black seed.[4] Many investigations have shown that TQ has anti-inflammation, anti-hypertensive, anti-asthmatic, anti-microbial, and anti-oxidant effects.[567] In addition, anticancer properties of TQ have also been reviewed and has been found that TQ applies anticancer effects (both in vitro and in vivo) in various patterns of carcinogenesis.[89] In earlier works, it was found that TQ prevents the growth of different types of cancer, including breast adenocarcinoma (multi-drug-resistant Michigan Cancer Foundation-7 [MCF-7]/TOPO, MCF-7, MDA-MB-231, and BT-474),[810] lung cancer (NCI-H460 and A549),[11] pancreatic cancer (MIA PaCa-2, HPAC, and BxPC-3),[11] and prostate cancer (LNCaP, C4-2B, and DU145).[121314] Several lines of studies have determined that TQ exhibits antimetastatic effects, and it can inhibit angiogenesis, in a way that, this compound was found to prevent C26 colon cancer cell invasion.[9] Moreover, some other studies have reported that TQ was able to suppress tumor growth in PC-3 prostate cancer cells, probably through angiogenesis inhibition and it can cause to significant reduction in the number of blood vessels in the tumor.[15] TQ has shown little effect on noncancerous cells such as mouse fibroblasts,[16] prostate epithelial cells,[12] human normal intestinal cells,[17] and human normal lung fibroblasts.[18] This result shows that TQ may have beneficial effects in different types of malignancy while has little effect on normal human cells. Shoieb et al. found that TQ induces apoptosis in osteosarcoma cells and also decrease the number of cells in S-phase. Hence, it induces the cell cycle arrest at G1-phase.[19] Other investigations have demonstrated that TQ can induce apoptosis via p53-dependent/independent pathways.[20212223] In spite of TQ good anti-neoplastic activities, the molecular mechanism of its pharmacologic effects is not fully understood. Gali-Muhtasib et al. investigated the effects of TQ against HCT-116 human colon cancer cells. They found that TQ induced apoptosis by up-regulating p53 and the downstream p53 target gene, p21WAF1.[20] Roepke et al. have shown that TQ induce apoptosis by p53-independent pathway.[23] Regarding increasing incidence of breast cancer in developing countries like Iran, many investigations have done on different cell line of breast cancer and many different ways have supposed for TQ induced apoptosis. Hence, in the present study, we hypothesized that TQ may up-regulate activity of P53 gene in breast cancer cell line MCF-7 that has a wild-type P53, and inhibit tumor cell growth.

METHODS

Cell lines, drug, culture, and treatment

Human breast cancer cell line (MCF-7) was purchased from the national cell bank of Iran-Pasteur Institute. TQ was purchased from Sigma (C6499, USA). Cell line used in the present study was cultured in Dulbecco's modified Eagle medium-F12 medium (Sigma) supplemented with 10% fetal bovine serum (Sigma) and 1% penicillin-streptomycin (Sigma), and incubated at 37°C and in humidified atmosphere containing 5% CO2. TQ was dissolved in minimum volume of dimethyl sulfoxide (DMSO) (2%) as working solution were prepared by adding of adequate water to reach the appropriate concentrations according to reported procedures.[2425] After the cells were >80% confluent and growing exponentially in flask 75, 105 cells (MCF-7) were counted and plated in flask 25 and kept in culture medium for 24 h which were then incubated with certain concentrations of TQ, based on half-maximal inhibitory concentration (IC50) index, at different times (24, 48, and 72 h).

Half-maximal inhibitory concentration assay

The IC50 values for the TQ in MCF-7 cells were acquired after 24 h of treatment. Briefly, 104 cells (MCF-7) were counted and placed into each well of a 12well microplate and were treated with various drug concentrations (0, 10, 20, 30, 40, 50, 60, 70, and 80 μM doses) for 24 h, and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) survival assay was done according to the protocol, for evaluating the cell viability in all cells.[2627] A graph of viability versus drug concentration was used to calculate IC50 values for MCF-7 cell line.[28]

Flow-cytometric analysis

Percentage of apoptotic cells was measured by flow cytometry following Annexin V flow cytometry 1-histogram (FL1-H) and propidium iodide (FL2-H) labeling. A minimum of 5 × 105 cells/ml were analyzed for each sample. Cells were treated with TQ (25 μmol/L) for 24, 48, and 72 h and so washed in phosphate-buffered saline and resuspended in binding buffer (10X; 5 μl). Annexin V-FITC was added to 195 μl cell suspensions, and so analysis was done according to the manufacturer's protocol (BMS500F1/100CE Annexin V-FITC Apoptosis Detection Kit - eBioscience, USA). Eventually, the apoptotic cells were counted by FACScan flow cytometry (Becton Dickinson, Heidelberg, Germany). These experiments were done in triplicate and were, independently, repeated at least 3 times.[2526]

Real-time polymerase chain reaction analysis

Real-time polymerase chain reaction (PCR) was performed to quantitatively assessment the messenger RNA (mRNA) expression of P53 gene in MCF-7 cells and after treatment with TQ at different times. Total RNA was isolated by RNeasy mini kit treated by RNase-Free DNase set (Qiagen) to remove the genomic DNA. The RNA concentration was defined using a BioPhotometer (Eppendorf BioPhotometer® D30). Total RNA (100 ng) was reverse-transcribed to complementary DNA (cDNA) using the RevertAid™ First Strand cDNA Synthesis Kit (Fermentas) according to the manufacturer's protocol. The maxima SYBR Green ROX qPCR Master Mix kit (Fermentas) was used for real-time PCR. Real-time PCR reactions were performed with using Step One Plus (Step One™ Real-Time PCR Systems - Applied Biosystems). The PCR amplification conditions consisted of 10 min at 95°C followed by 40 cycles of denaturation step at 95°C for 15 s and annealing and extension for 1 min at 60°C. This data were analyzed using the comparative Ct (ΔΔCt) method. The relative expression level of P53 was calculated by determining a ratio between the amount of P53 and that of endogenous control (glyceraldehyde-3-phosphate dehydrogenase [GAPDH]). Melting curve analysis (60°C → 95°C increment of 0.3°C) was used to determine the melting temperature of special amplification products and primer dimers. These experiments were done in triplicate and were independently repeated at least 3 times.[27] Primer sequences for P53 and GAPDH were as follow:[29] PF GAPDH: CACCACCATGGAGAAGGCTGG PR GAPDH: CCAAAGTTGTCATGGATGACC PF P53: CGAGTCCCGCGGTAATTCTT PR P53: TGCAGAAGAGGTGCAAGACC.

Statistical analysis

All the quantitative data were presented as the mean ± standard deviation. Repeated measure analysis of variance with post hoc test was performed to determine the statistical significance among different groups using the SPSS software package 20.0 IBM modeler (2009). Significance was accepted at a level of P < 0.05.

RESULTS

Half-maximal inhibitory concentration analysis

After the treatment of MCF-7 cells with MTT solution in this study, the dark blue formazan crystals were seen in cells, which indicated their metabolic activity. The reduction in the number of cells was dependent on the cell type as shown by the IC50 index. The IC50 value for the TQ was established. The results showed that the essential TQ concentration to achieve the IC50 in MCF-7 cells at 24 h was 25 μmol/L [Figure 1].
Figure 1

Half-maximal inhibitory concentration assay for half-maximal inhibitory concentration analysis of thymoquinone in Michigan Cancer Foundation-7 cancer cell lines after 24 h of treatment. Cells were incubated with or without the thymoquinone using 25 μM dose. The relative amount of viable cells was estimated by measuring the absorbance of the cell suspension after incubation with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. A graph of viability versus drug concentration was used to calculate half-maximal inhibitory concentration values for Michigan Cancer Foundation-7 cell line

Half-maximal inhibitory concentration assay for half-maximal inhibitory concentration analysis of thymoquinone in Michigan Cancer Foundation-7 cancer cell lines after 24 h of treatment. Cells were incubated with or without the thymoquinone using 25 μM dose. The relative amount of viable cells was estimated by measuring the absorbance of the cell suspension after incubation with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. A graph of viability versus drug concentration was used to calculate half-maximal inhibitory concentration values for Michigan Cancer Foundation-7 cell line

Flow cytometry

To establish the anti-apoptosis potential of the TQ, we first investigated the effects of TQ on the proliferation in MCF-7 cells. The flow cytometry results showed that TQ at different time points (24, 48 and 72 h) could induce apoptosis in MCF-7 cells, and it was increased with ascending time. TQ arrested MCF-7 cells proliferation (40% of inhibition) in 72 h and (approximately 30% of inhibition) in 48 h [Figure 2a and b, P < 0.05]. DMSO was used in the control sample (vehicle drugs). Using Dunnett test, average of apoptotic cells at different times were compared with the control group. Groups 48 h and 72 h had significant difference to the control group (*P < 0.05).
Figure 2

(a) Relative levels of apoptotic cells in Michigan Cancer Foundation-7 treated with thymoquinone for different times. Cells incubated with the vehicle dimethyl sulfoxide were used as a control. The percentage of apoptotic cells was measured using the Annexin V-FITC flow cytometry 1-histogram and propidium iodide flow cytometry 2-histogram. Dunnett's test was used for considered comparisons (*P < 0.05) (in any figure, right upper quarter show late apoptotic cells, left upper quarter show necrosis cells, right lower quarter show early apoptotic cells and left lower quarter show normal cells). (b) Cells that are Annexin V-positive and propidium iodide negative are in early apoptosis as phosphatidyl serine translocation has occurred; although, the plasma membrane remains intact. Cells that are positive for both Annexin V and propidium iodide either are in the late stages of apoptosis or are already dead as phosphatidyl serine translocation has occurred and the loss of plasma membrane integrity is visible. *P < 0.05 compared to controls. Dunnett's test was used for considered comparisons (*P < 0.05)

(a) Relative levels of apoptotic cells in Michigan Cancer Foundation-7 treated with thymoquinone for different times. Cells incubated with the vehicle dimethyl sulfoxide were used as a control. The percentage of apoptotic cells was measured using the Annexin V-FITC flow cytometry 1-histogram and propidium iodide flow cytometry 2-histogram. Dunnett's test was used for considered comparisons (*P < 0.05) (in any figure, right upper quarter show late apoptotic cells, left upper quarter show necrosis cells, right lower quarter show early apoptotic cells and left lower quarter show normal cells). (b) Cells that are Annexin V-positive and propidium iodide negative are in early apoptosis as phosphatidyl serine translocation has occurred; although, the plasma membrane remains intact. Cells that are positive for both Annexin V and propidium iodide either are in the late stages of apoptosis or are already dead as phosphatidyl serine translocation has occurred and the loss of plasma membrane integrity is visible. *P < 0.05 compared to controls. Dunnett's test was used for considered comparisons (*P < 0.05)

Real-time polymerase chain reaction

It was suggested that apoptotic induction in cancer cells by TQ requires the activation of P53 gene expression. To examine this hypothesis, we used MCF-7 cell line, as cancerous cell line. We examined the inhibitory effects of 25 μmol/L TQ (based on IC50 index) at different times on the mRNA expression of P53 in MCF-7 cell line. The P53 gene expression was dramatically up-regulated by ascending time, in particular, at 72 h treatment its expression was increased significantly [Figure 3, P < 0.05]. Using Dunnett test, average of P53 gene expression at different times was compared with the control group. Groups 48 h and 72 h had significant difference to the control group (*P < 0.05).
Figure 3

Results of real-time quantitative polymerase chain reaction before and after thymoquinone treatment at different times on the P53 messenger RNA expression in Michigan Cancer Foundation-7 cell. Relative expression levels were obtained using the comparative Ct (ΔΔCt) method (*P < 0.05)

Results of real-time quantitative polymerase chain reaction before and after thymoquinone treatment at different times on the P53 messenger RNA expression in Michigan Cancer Foundation-7 cell. Relative expression levels were obtained using the comparative Ct (ΔΔCt) method (*P < 0.05)

DISCUSSION

Breast cancer is the most common cancer among women worldwide and it is one of the most common cancers that lead to death.[3031] Therefore, many continuous searches have done for usage of new chemotherapeutic drugs in this type of cancer.[32] Over the centuries, different plant species have been used for chemotherapy.[3334] Several lines of studies have shown cytotoxicity effects of N. sativa against various carcinomas.[353637] TQ as an active ingredient isolated from N. sativa has tested for its efficacy against cancer.[19] To date, many studies have demonstrated that this compound can inhibit the growth of many different types of cancer, including glioma/glioblastoma (U87 MG),[1838] breast adenocarcinoma (multi-drug-resistant MCF-7/TOPO, MCF-7),[810] leukemia (HL-60 and Junket),[8] lung cancer (NCI-H460),[11] colorectal carcinoma (HT-29),[1117] and pancreatic cancer (HPAC and BxPC-3).[11] In the present study, we investigated the effect of TQ on P53 gene expression and consequence apoptosis in breast cancer cell line. TQ molecular mechanisms are not fully understood. However, the assumptions indicated that the anti-tumor effect of TQ may happen by one or more of the following mechanisms, antioxidant activity and cytotoxicity.[39] The results of the present study showed that TQ inhibits the viability and proliferation of breast cancer cell line by a time-dependent manner. Many studies demonstrated that TQ induces apoptosis in p53-dependent or p53-independent pathway.[20212223] Mansour and Tornhamre and Badary et al. have shown TQ property as a radical scavenger with a potential role in the prevention and treatment of oxidative stress.[4041] A number of studies have shown that TQ could prevent from chemical effects of cancer and inhibit tumorigenesis through different molecular mechanisms.[42] Apoptosis is one form of physiological or a key pathway for regulating homeostasis and morphogenesis of cells and is related to cancer.[43] Numerous in vitro and in vivo studies have indicated that TQ has anti-proliferative effects and can induce cell cycle arrest and also induces pro-apoptotic effects in cancer cells.[2344] Woo CC et al. have reported that the apoptotic effect of TQ is p53-independent in p53-null myeloblastic leukemia HL-60 cells.[10] They also confirmed that the apoptotic effect of TQ in leukemia cells is caspase-dependent. In some other studies, TQ induces apoptosis through the expression of p53 gene in HCT116 human colorectal carcinoma cells.[20] Thus, the results of different studies show that the anticancer activity of TQ is dependent on cell type. The potencies and functional mechanisms of the TQ were studied at the concentration that was confirmed by IC50 on the MCF-7 as breast cancer cell line. In recent years, a few researchers have described the therapeutic effect of TQ by p53 up-regulation in different cell line;[45] here, we report for the first time that TQ was able to up-regulate the p53 expression in MCF-7 cell line. To understand the inhibitory effect of TQ in breast cancer cells, we used different molecular techniques. In the present study, we have shown that TQ induce apoptosis in MCF-7 cells via time-dependent manner. In addition, real-time PCR results on MCF-7 cells, showed apoptotic induction in cancer cells by TQ requires the activation of P53 gene expression as it was dramatically up-regulated by ascending time, in particular, at 72 h treatment its expression was increased significantly (P < 0.001). In this study, treatment by TQ at various time showed a time-dependent increase in apoptotic cell count of the cancerous cells, as measured by flow-cytometric assay. We have found that TQ caused a significant up-regulation p53 in a time-dependent manner. Our results were supported by the findings of Gali-Muhtasib et al., which indicated that TQ is anti-neoplastic and pro-apoptotic against colon cancer cell line HCT116, and the apoptotic effects of TQ are dependent on p53.[20] Our results were matched with the findings of Woo et al. which stated that TQ exerted strong anti-proliferative effect in breast cancer cells.[10] In addition, they found that TQ activated caspases 8, 9, and 7 in a dose-dependent manner (possible involvement of peroxisome proliferator activated receptor-γ [PPAR-γ] pathway). Besides, El-Mahdy et al. have reported that TQ exhibits antiproliferative effect, induces apoptosis and triggers the activation of caspases 8, 9, and 3 inmyeloblastic leukemia HL-60 cells (p53-independent).[10] Taken together, our results indicated that TQ inhibited breast cancer cell proliferation in a time-dependent manner. Also, for the first time, we have shown that TQ induce apoptosis through activation of the P53 pathway in MCF-7 cell line. Further, it is required to evaluate the effect of TQ on prevention and treatment of breast cancer.

CONCLUSIONS

The results showed that the drug's effect was significant at 48 and 72 hours. Finally, TQ treatment for 72 hours would have to make the most of apoptosis by expression of P53 gene and it's Resumption of activities apoptotic. Considering the valuable properties of the drug, can be hope to the emergence of a new strategy in the fight against cancer.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  45 in total

1.  Anticancer activity of thymoquinone in breast cancer cells: possible involvement of PPAR-γ pathway.

Authors:  Chern Chiuh Woo; Ser Yue Loo; Veronica Gee; Chun Wei Yap; Gautam Sethi; Alan Prem Kumar; Kwong Huat Benny Tan
Journal:  Biochem Pharmacol       Date:  2011-06-14       Impact factor: 5.858

2.  Combinatorial effects of thymoquinone on the anti-cancer activity of doxorubicin.

Authors:  Katharina Effenberger-Neidnicht; Rainer Schobert
Journal:  Cancer Chemother Pharmacol       Date:  2010-06-26       Impact factor: 3.333

3.  Antioxidant activity of Nigella sativa essential oil.

Authors:  M Burits; F Bucar
Journal:  Phytother Res       Date:  2000-08       Impact factor: 5.878

4.  The influence of thymoquinone on doxorubicin-induced hyperlipidemic nephropathy in rats.

Authors:  O A Badary; A B Abdel-Naim; M H Abdel-Wahab; F M Hamada
Journal:  Toxicology       Date:  2000-03-07       Impact factor: 4.221

5.  Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species.

Authors:  Padma Sandeep Koka; Debasis Mondal; Michelle Schultz; Asim B Abdel-Mageed; Krishna C Agrawal
Journal:  Exp Biol Med (Maywood)       Date:  2010-06

Review 6.  A matter of life and cell death.

Authors:  G Evan; T Littlewood
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

7.  Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

Authors:  Ivan V Gregoretti; Yun-Mi Lee; Holly V Goodson
Journal:  J Mol Biol       Date:  2004-04-16       Impact factor: 5.469

8.  Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes.

Authors:  Hala U Gali-Muhtasib; Wassim G Abou Kheir; Lynn A Kheir; Nadine Darwiche; Peter A Crooks
Journal:  Anticancer Drugs       Date:  2004-04       Impact factor: 2.248

9.  Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer.

Authors:  Ahmed O Kaseb; Kannagi Chinnakannu; Di Chen; Arun Sivanandam; Sheela Tejwani; Mani Menon; Q Ping Dou; G Prem-Veer Reddy
Journal:  Cancer Res       Date:  2007-08-15       Impact factor: 12.701

10.  Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database.

Authors:  Philippe Autier; Mathieu Boniol; Anna Gavin; Lars J Vatten
Journal:  BMJ       Date:  2011-07-28
View more
  16 in total

1.  Upregulation of CD271 transcriptome in breast cancer promotes cell survival via NFκB pathway.

Authors:  Nabiha Bashir; Mehreen Ishfaq; Kehkashan Mazhar; Jahangir Sarwar Khan; Ramla Shahid
Journal:  Mol Biol Rep       Date:  2021-11-09       Impact factor: 2.316

Review 2.  Black Cumin (Nigella sativa L.): A Comprehensive Review on Phytochemistry, Health Benefits, Molecular Pharmacology, and Safety.

Authors:  Md Abdul Hannan; Md Ataur Rahman; Abdullah Al Mamun Sohag; Md Jamal Uddin; Raju Dash; Mahmudul Hasan Sikder; Md Saidur Rahman; Binod Timalsina; Yeasmin Akter Munni; Partha Protim Sarker; Mahboob Alam; Md Mohibbullah; Md Nazmul Haque; Israt Jahan; Md Tahmeed Hossain; Tania Afrin; Md Mahbubur Rahman; Md Tahjib-Ul-Arif; Sarmistha Mitra; Diyah Fatimah Oktaviani; Md Kawsar Khan; Ho Jin Choi; Il Soo Moon; Bonglee Kim
Journal:  Nutrients       Date:  2021-05-24       Impact factor: 5.717

3.  Thymoquinone Suppresses Cell Proliferation and Enhances Apoptosis of HL60 Leukemia Cells through Re-Expression of JAK/STAT Negative Regulators.

Authors:  Belal Almajali; Hamid Ali Nagi Al-Jamal; Wan Rohani Wan Taib; Imilia Ismail; Muhammad Farid Johan; Abd Almonem Doolaanea; Wisam Nabeel Ibrahim; Syed Ahmad Tajudin
Journal:  Asian Pac J Cancer Prev       Date:  2021-03-01

Review 4.  North African Medicinal Plants Traditionally Used in Cancer Therapy.

Authors:  Jorge M Alves-Silva; Abderrahmane Romane; Thomas Efferth; Lígia Salgueiro
Journal:  Front Pharmacol       Date:  2017-06-26       Impact factor: 5.810

5.  Thymoquinone Inhibits the Migration and Invasive Characteristics of Cervical Cancer Cells SiHa and CaSki In Vitro by Targeting Epithelial to Mesenchymal Transition Associated Transcription Factors Twist1 and Zeb1.

Authors:  Jun Li; Md Asaduzzaman Khan; Chunli Wei; Jingliang Cheng; Hanchun Chen; Lisha Yang; Iqra Ijaz; Junjiang Fu
Journal:  Molecules       Date:  2017-12-04       Impact factor: 4.411

6.  Senescent Colon and Breast Cancer Cells Induced by Doxorubicin Exhibit Enhanced Sensitivity to Curcumin, Caffeine, and Thymoquinone.

Authors:  Ali H El-Far; Noureldien H E Darwish; Shaker A Mousa
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279

7.  Cytotoxic and antiproliferative effects of thymoquinone on rat C6 glioma cells depend on oxidative stress.

Authors:  N G Krylova; M S Drobysh; G N Semenkova; T A Kulahava; S V Pinchuk; O I Shadyro
Journal:  Mol Cell Biochem       Date:  2019-09-06       Impact factor: 3.396

Review 8.  Thymoquinone, as an anticancer molecule: from basic research to clinical investigation.

Authors:  Md Asaduzzaman Khan; Mousumi Tania; Shangyi Fu; Junjiang Fu
Journal:  Oncotarget       Date:  2017-04-18

9.  Thymoquinone synergizes gemcitabine anti-breast cancer activity via modulating its apoptotic and autophagic activities.

Authors:  Hanan A Bashmail; Aliaa A Alamoudi; Abdulwahab Noorwali; Gehan A Hegazy; Ghada AJabnoor; Hani Choudhry; Ahmed M Al-Abd
Journal:  Sci Rep       Date:  2018-08-03       Impact factor: 4.379

10.  Regressions of Breast Carcinoma Syngraft Following Treatment with Piperine in Combination with Thymoquinone.

Authors:  Wamidh H Talib
Journal:  Sci Pharm       Date:  2017-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.